Changes in depression symptom profile with gender-affirming hormone use in transgender persons 101 3.4. Baseline IDS-SR scores for missing participants at 3- and 12-month follow ups Due to the ongoing character of the study and loss to follow-up, the sample sizes after baseline are lower. Scores were compared using the nonparametric Mann-Whitney U test. In Supplementary Table S3.5, we describe the IDS-SR baseline scores stratified by participation in follow-ups and the participation rates per measurement time point and group (i.e. how many participants completed the follow-up questionnaire). IDS-SR baseline scores of participants who participated in the 3- or 12-month follow-ups compared to those missing at follow ups were not different in the TM group at the 3-month follow-up (p=0.91) or 12-month follow-up (p=0.96), nor in the TF group at the 3-month follow-up (p=0.60) or 12-month follow-up (p=0.19). Table S3.5. Comparison of IDS-SR baseline scores between participants who contributed to follow-ups after 3 and 12 months of GHAT compared to participants who did not to follow-ups at 3 or 12 months of GAHT use. n Baseline IDS-SR score (Median, IQR) Baseline IDS-SR missing (n) Participation rate at measurement time point 3-month measurement in TM group Contributed IDS-SR at 3-month follow-up 84 15 (10 to 27.5) 14 84 / (110-1)=77.1% Missing IDS-SR at 3month follow-up 25 16.5 (8.3 to 32.8) 3 Did not reach 3-month follow up yet 1 8 (8 to 8) 0 12-month measurement in TM group Contributed IDS-SR at 12-month follow-up 62 15 (10 to 25.5) 8 62 / (110-17)=66.7% Missing IDS-SR at 12month follow-up 31 14 (8.5 to 24.5) 8 Did not reach 12month follow up yet 17 15 (9.5 to 32.8) 1 3-month measurement in TF group Contributed IDS-SR at 3-month follow-up 64 11.5 (6.3 to 20.5) 10 64 / (89–3)=74.4% Missing IDS-SR at 3month follow-up 22 10 (7.3 to 27) 8 Did not reach 3-month follow up yet 3 12 (1 to 32) 1 12-month measurement in TF group Contributed IDS-SR at 12-month follow-up 43 10 (6 to 18.5) 12 43 / (89–26)=68.3% Missing IDS-SR at 12month follow-up 20 12.5 (8.5 to 19.5) 4 Did not reach 12month follow up yet 26 14 (8 to 28) 2
RkJQdWJsaXNoZXIy MTk4NDMw